Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Anne Lethaby"'
Autor:
Magdalena Bofill Rodriguez, Sofia Dias, Vanessa Jordan, Anne Lethaby, Sarah F Lensen, Michelle R Wise, Jack Wilkinson, Julie Brown, Cindy Farquhar
Publikováno v:
Cochrane Database Syst Rev
BACKGROUND: Heavy menstrual bleeding (HMB) is excessive menstrual blood loss that interferes with women's quality of life, regardless of the absolute amount of bleeding. It is a very common condition in women of reproductive age, affecting 2 to 5 of
Publikováno v:
Cochrane Database Syst Rev
Background Within the context of heavy menstrual bleeding, pandemics impact upon women's assessment and treatment by healthcare providers. Objectives To summarise the evidence from Cochrane Reviews evaluating interventions for heavy menstrual bleedin
Publikováno v:
The Cochrane database of systematic reviews. 6
Background Heavy menstrual bleeding (HMB) impacts the quality of life of otherwise healthy women. The perception of HMB is subjective and management depends upon, among other factors, the severity of the symptoms, a woman's age, her wish to get pregn
Publikováno v:
Cochrane Database of Systematic Reviews. 2019
Background Menorrhagia or heavy menstrual bleeding (HMB) is an excessive blood loss that impairs a woman's quality of life, either physical, emotional, social or material. It is benign and not associated with pregnancy or any other gynaecological or
Autor:
Hernando Gaitán, Juan Pablo Alzate, Anne Lethaby, Jorge Andrés Rubio-Romero, Carol Páez-Canro, Lina M González
Publikováno v:
The Cochrane Library
Background The genital infection caused by Chlamydia trachomatis (CT) is a common sexually transmitted infection (STI) globally. The infection is mainly asymptomatic in women, thus it can produce infertility and chronic pelvic pain. In men infection
Autor:
Martha Hickey, Magdalena Bofill Rodriguez, Mihaela Grigore, Cindy Farquhar, Julie Brown, Anne Lethaby
Publikováno v:
Scopus-Elsevier
The Cochrane Library
The Cochrane Library
BACKGROUND: Heavy menstrual bleeding (HMB) is a significant health problem in premenopausal women; it can reduce their quality of life and can cause social disruption and physical problems such as iron deficiency anaemia. First‐line treatment has t
Autor:
Jack Wilkinson, Cindy Farquhar, Anne Lethaby, Michelle R. Wise, Sofia Dias, Sarah Lensen, Julie Brown, Magdalena Bofill Rodriguez, Vanessa Jordan
Publikováno v:
Cochrane Database of Systematic Reviews.
This is a protocol for a Cochrane Review (Overview). The objectives are as follows:. To identify, systematically assess and summarise all evidence from Cochrane Reviews on treatment for heavy menstrual bleeding (HMB), through a network meta-analysis.
Publikováno v:
Heart. 104:93-95
Hormone therapy (HT) has been used for over 50 years for treating menopausal vasomotor symptoms, and its efficacy is well established. HT consists of oestrogen either alone or combined with a progestogen. Progestogen use reduces the risk of endometri
Publikováno v:
The Cochrane Library
Scopus-Elsevier
Scopus-Elsevier
BACKGROUND: Heavy menstrual bleeding (HMB) is an important physical and social problem for women. Oral treatment for HMB includes antifibrinolytic drugs, which are designed to reduce bleeding by inhibiting clot‐dissolving enzymes in the endometrium
Publikováno v:
The Cochrane Library
Background Uterine fibroids occur in up to 40% of women aged over 35 years. Some are asymptomatic, but up to 50% cause symptoms that warrant therapy. Symptoms include anaemia caused by heavy menstrual bleeding, pelvic pain, dysmenorrhoea, infertility